Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
just 13 quarters after launch, yet penetration remains small at about 0.2% of the antidepressant market ; Axsome plans to double its salesforce from 300 to 600 reps to drive further uptake and support a potential Alzheimer's agitation launch. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with a PDUFA date of April 30 , and the submission includes long-term safety data (~100 patients at 12 months, ~300 at six months). Management reported strong financial traction—revenues outpaced operating expense growth 3-to-1 in 2025—and expects continued operating leverage despite higher DTC spending that raised SG&A from ~$150 million in Q3 to nearly $170 million in Q4, with 2026 spending forecast between those levels. Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better. Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out Axsome Therapeutics (NASDAQ:AXSM) executives highlighted expanding commercial momentum for
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (AXSM) had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a "buy" rating on the stock.MarketBeat
- Is This Healthcare Stock a Millionaire Maker? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Is This Healthcare Stock a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswire
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswire
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- AXSM's page on the SEC website